SCHEMBL29686247

SCHEMBL29686247

CC(C)(C)[S@@+]([O-])/N=C/c1ccc(C(F)(F)F)cn1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.35
RAB9A P51151 6/20 0.35
MAPT P10636 6/20 0.35
MEN1 O00255 5/20 0.35
NPC1 O15118 5/20 0.35
SMN1; SMN2 Q16637 5/20 0.35
GAA P10253 4/20 0.35
CDK5 Q00535 3/20 0.35
CDK5R1 Q15078 3/20 0.35
GFER P55789 1/20 0.35
TDP1 Q9NUW8 2/20 0.33
HPGD P15428 1/20 0.33
ALDH1A1 P00352 3/20 0.33
POLB P06746 1/20 0.32
HTT P42858 1/20 0.32
KDM4E B2RXH2 3/20 0.32
LMNA P02545 1/20 0.32
TSHR P16473 1/20 0.31
AGTR1 P30556 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27160139 1.00 KMT2A (0.35) KMT2ARAB9AMAPTMEN1NPC1
SCHEMBL27160144 1.00 KMT2A (0.35) KMT2ARAB9AMAPTMEN1NPC1
SCHEMBL29106363 1.00 KMT2A (0.35) KMT2ARAB9AMAPTMEN1NPC1
SCHEMBL29106366 1.00 KMT2A (0.35) KMT2ARAB9AMAPTMEN1NPC1
SCHEMBL347790 0.82 HTR2A (0.31)
SCHEMBL3775396 0.82 HTR2A (0.31)
SCHEMBL3775400 0.82 HTR2A (0.31)
SCHEMBL347791 0.82 HTR2A (0.31)
SCHEMBL30962424 0.82 HTR2A (0.31)
SCHEMBL17819857 0.80 CCR1 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024220917-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2024-10-24 WO disclosed
EP-4251624-A1 TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS Amgen, Inc (US) 2023-10-04 EP disclosed
WO-2022115377-A1 TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS AMGEN INC. (US) 2022-06-02 WO disclosed